<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096573</url>
  </required_header>
  <id_info>
    <org_study_id>LG-SGCL002</org_study_id>
    <nct_id>NCT04096573</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis</brief_title>
  <official_title>A Phase 2, Multi Center, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Clinical Efficacy and Safety of LC51 0255 in Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi center, randomized, placebo controlled parallel group study to
      evaluate the clinical efficacy and safety of LC51 0255 in subjects with moderately to
      severely active ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Week 12</time_frame>
    <description>The proportion of subjects in clinical remission assessed by Mayo component sub-scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 12</time_frame>
    <description>The proportion of subjects in clinical response assessed by Mayo component sub-scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic improvement and remission</measure>
    <time_frame>Week 12</time_frame>
    <description>The proportion of subjects in endoscopic improvement and remission assessed by Mayo endoscopic sub-score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical response and remission</measure>
    <time_frame>Week 52</time_frame>
    <description>The proportion of subjects in clinical response and remission assessed by Mayo component sub-scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Endoscopic improvement and remission</measure>
    <time_frame>Week 52</time_frame>
    <description>The proportion of subjects in endoscopic improvement and remission assessed by Mayo endoscopic sub-score</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>LC51-0255 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral, daily, low dose for induction period, high dose for OLE period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC51-0255 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral, daily, middle dose for induction period, high dose for OLE period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC51-0255 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral, daily, high dose for induction period, high dose for OLE period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral, daily, placebo for induction period, high dose for OLE period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC51-0255</intervention_name>
    <description>LC51-0255</description>
    <arm_group_label>LC51-0255 high dose</arm_group_label>
    <arm_group_label>LC51-0255 low dose</arm_group_label>
    <arm_group_label>LC51-0255 middle dose</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 80 years

          -  Active UC confirmed by endoscopy

          -  Moderately to severely active UC defined as a 3-component Mayo Clinic score

        Exclusion Criteria:

          -  Severe extensive colitis

          -  Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

          -  Treatment with cyclosporine, tacrolimus, sirolimus, methotrexate, or mycophenolate
             mofetil within 16 weeks of screening

          -  Treatment with a biologic agent (ie, anti TNFs, anti integrins, and anti interleukin
             23) within 8 weeks prior to screening endoscopy

          -  Any prior exposure to S1P receptor modulators, natalizumab, lymphocyte-depleting
             therapies (ie, alemtuzumab, anti CD4, cladribine, rituximab, ocrelizumab,
             cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation,
             alemtuzumab, daclizumab)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suyeon Ko</last_name>
    <phone>+82 2 6987 4150</phone>
    <email>suyeon@lgchem.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

